Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Sophia Nessow
London +44 20 7067 2231 snessow@cov.com Download V-card

Sophia Nessow is an associate in the corporate practice group in Covington’s London office, having joined the firm as a trainee solicitor in 2015.

Ms. Nessow advises private and public companies on a broad range of corporate, transactional and advisory matters including capital markets transactions, joint ventures, mergers and acquisitions, corporate restructurings, corporate governance, and general corporate and commercial advisory work, with a particular focus on the life sciences and technology industries.

  • Acted for Oxford BioMedica plc, a leading gene and cell therapy company listed on the London Main Market, in a placing and subscription to raise gross proceeds of £11.5 million.
  • Acted for a specialty AIM-listed pharmaceutical company on a follow-on financing of £40 million undertaken by way of a placing.
  • Advised a NASDAQ-listed multinational information technology company on the implementation of human rights initiatives, including the drafting of transparency statements for the purposes of the UK Modern Slavery Act.
  • Advised a digital health platform provider in connection with its corporate restructuring.
  • Acted for an AIM-listed cloud-based global video distribution and monetisation network on a follow-on placing.
  • Represented a leading life sciences company listed on the London Stock Exchange in connection with the negotiation of an immuno-oncology joint venture.
  • Acted for a private company developing cancer therapies on a venture capital financing of up to £25 million.
  • Represented a private immuno-oncology drug company in relation to a Series A financing of up to £12 million from a venture investor consortium.

Pro Bono

  • Advising an undocumented child in connection with her application for British citizenship.
  • Represented a UK charity for deaf people in its defence of claims for unpaid overtime and annual leave brought in the Employment Tribunal by a former employee.
  • Advised a UK lung disease charity regarding its redundancy procedures.
  • Represented an international campaigning and advocacy organization in connection with the negotiation of a commercial lease for its UK premises.